[BUSINESS]■ STORY TIMELINE
MODERNA'S mRNA FLU SHOT WINS FDA APPROVAL
The FDA has approved Moderna's mFLUSIVA, an mRNA-based flu vaccine for adults 50 and older. The approval marks the first seasonal flu vaccine using messenger RNA technology.
Ars Technica+0m
Moderna's new flu vaccine, mFLUSIVA, is approved for all adults ages 50 and up.